Gain Therapeutics (GANX) Non-Current Debt (2020 - 2026)

Gain Therapeutics has reported Non-Current Debt for 7 years, with the latest figure at $220058.0 in Q2 2026.

• On a quarterly basis, Non-Current Debt fell 32.36% year-over-year to $220058.0 in Q2 2026; TTM through Jun 2026 was $220058.0, a 32.36% decrease from a year earlier, with the FY2025 full-year figure at $300084.0, down 8.6% from the prior year.
• Non-Current Debt was $220058.0 for Q2 2026 at Gain Therapeutics, down from $273265.0 in the prior quarter.
• The five-year high for Non-Current Debt was $560889.0 in Q1 2022, with the low at $220058.0 in Q2 2026.
• Average Non-Current Debt over 5 years is $395557.9, with a median of $386483.0 recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt retreated 8.6% in 2025, then tumbled 32.36% in 2026.
• Over 5 years, Non-Current Debt stood at $495258.0 in 2022, then dropped by 9.33% to $449053.0 in 2023, then slipped by 26.88% to $328327.0 in 2024, then declined by 8.6% to $300084.0 in 2025, then declined by 26.67% to $220058.0 in 2026.
• The last three Non-Current Debt figures came in at $220058.0 (Q2 2026), $273265.0 (Q1 2026), and $300084.0 (Q4 2025), per Business Quant data.